Proactive Investors - Run By Investors For Investors

Anatara Lifesciences to outline its new strategy in human health at Proactive CEO Sessions

Following the successful licencing of its animal health product to Zoetis Inc, Anatara is now focused on building a pipeline of human gastrointestinal health products.
Steven Lydeamore
The company’s chief executive officer Steven Lydeamore will address investors at the CEO Sessions

Anatara Lifesciences Ltd (ASX:ANR) is focused on its new business strategy in human health, and in particular the development and partnering of its GaRP dietary supplement.

The company will outline its progress and strategy during this month’s Proactive CEO Sessions. Chief executive officer Steven Lydeamore will present to investors at the Melbourne CEO Session on Tuesday, February 19.

Lydeamore has 26 years’ international experience in the pharmaceutical industry, working in Australia, USA and Canada. He brings a strong track record of successfully commercialising products on a global scale.

Anatara’s product candidate GaRP is an evidence-based dietary supplement aimed at restoring and maintaining gut health. It is well advanced in proof of concept studies.

With foundations built on strong and successful science, GaRP has been designed to address the primary underlying factors associated with gastrointestinal disorders such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).

 

Animal health to human health

In October 2018, Anatara had received approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA) for its animal health product licensed to Zoetis Inc.

The animal health product Detach has the approved label, “To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets”.

Following the successful licencing of its first product to Zoetis Inc, Anatara is now focused on building a pipeline of human gastrointestinal health products.

Register for the CEO Sessions today to find out more.

Melbourne details, Tuesday, February 19, 2019

Also featuring at the event will be Kazia Therapeutics Ltd (ASX:KZA), Peninsula Energy Ltd (ASX:PEN) and AdAlta Ltd (ASX:1AD).

View full ANR profile View Profile

Anatara Lifesciences Ltd Timeline

Related Articles

scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.
Cancer cells
February 07 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use